BeiGene Ltd.

196.64+5.26+2.75%Vol 159.12K1Y Perf -31.58%
Aug 11th, 2022 16:00 DELAYED
BID180.00 ASK204.00
Open197.90 Previous Close191.38
Pre-Market- After-Market204.00
 - -  7.36 3.74%
Target Price
288.67 
Analyst Rating
Moderate Buy 1.75
Potential %
46.80 
Finscreener Ranking
★★★+     50.86
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★     46.98
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★+     49.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
25.44 
Earnings Rating
Strong Buy
Market Cap20.41B 
Earnings Date
4th Aug 2022
Alpha0.03 Standard Deviation0.18
Beta0.72 

Today's Price Range

194.25207.27

52W Range

118.18426.56

5 Year PE Ratio Range

-36.70-17.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.12%
1 Month
10.06%
3 Months
49.56%
6 Months
-2.78%
1 Year
-31.58%
3 Years
45.28%
5 Years
176.88%
10 Years
-

TickerPriceChg.Chg.%
BGNE196.645.26002.75
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-75.60
-222.60
-216.50
-280.90
-86.01
RevenueValueIndustryS&P 500US Markets
727.05M
7.03
218.50
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-4.23-5.56-31.44
Q01 2022-4.52-4.246.19
Q04 2021-4.79-6.16-28.60
Q03 2021-4.82-4.467.47
Q02 2021-3.71-5.23-40.97
Q01 2021-3.350.69120.60
Q04 2020-4.03-5.20-29.03
Q03 2020-4.11-4.81-17.03
Earnings Per EndEstimateRevision %Trend
6/2022 QR-4.169.17Positive
9/2022 QR-3.8514.82Positive
12/2022 FY-15.76-0.64Negative
12/2023 FY-12.43-0.24Negative
Next Report Date-
Estimated EPS Next Report-4.23
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume159.12K
Shares Outstanding103.82K
Shares Float91.53M
Trades Count5.08K
Dollar Volume31.81M
Avg. Volume252.61K
Avg. Weekly Volume225.33K
Avg. Monthly Volume236.33K
Avg. Quarterly Volume296.18K

BeiGene Ltd. (NASDAQ: BGNE) stock closed at 196.64 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 159.12K shares and market capitalization of 20.41B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.

The one-year performance of BeiGene Ltd. stock is -31.58%, while year-to-date (YTD) performance is -27.42%. BGNE stock has a five-year performance of 176.88%. Its 52-week range is between 118.18 and 426.56, which gives BGNE stock a 52-week price range ratio of 25.44%

BeiGene Ltd. currently has a PE ratio of -8.80, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 24.57, a price to cashflow ratio of 605.70, a PEG ratio of 2.32, a ROA of -28.32%, a ROC of -34.18% and a ROE of -39.61%. The company’s profit margin is -86.01%, its EBITDA margin is -216.50%, and its revenue ttm is $727.04 Million , which makes it $7.03 revenue per share.

Of the last four earnings reports from BeiGene Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-4.23 for the next earnings report. BeiGene Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BeiGene Ltd. is Moderate Buy (1.75), with a target price of $288.67, which is +46.80% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BeiGene Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.89, ATR14 : 12.53, CCI20 : 133.34, Chaikin Money Flow : 0.01, MACD : 6.78, Money Flow Index : 51.58, ROC : 10.91, RSI : 49.71, STOCH (14,3) : 76.99, STOCH RSI : 0.85, UO : 57.70, Williams %R : -23.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: John V. Oyler (Sold 347 803 shares of value $10 022 365 ), Lai Wang (Option Excercise at a value of $4 025 737)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (50.00 %)
3 (50.00 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Hold
2 (33.33 %)
2 (33.33 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.75
Moderate Buy
1.75
Moderate Buy
1.75

BeiGene Ltd.

BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

CEO: John V. Oyler

Telephone: +1 345 949-4123

Address: c/o Mourant Governance Services (Cayman) Limited, Grand Cayman KY1-1108, , KY

Number of employees: 5 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

61%39%

TipRanks News for BGNE

Fri, 15 Jul 2022 16:47 GMT BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley

- TipRanks. All rights reserved.

Fri, 08 Jul 2022 02:48 GMT BeiGene (BGNE) Receives a Hold from SVB Securities

- TipRanks. All rights reserved.

Sat, 09 Apr 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Eledon Pharmaceuticals (ELDN) and Nurix Therapeutics (NRIX)

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), LHC Group (LHCG) and Natera (NTRA)

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 12:41 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), ICU Medical (ICUI) and Universal Health (UHS)

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 16:32 GMT BeiGene (BGNE) Receives a Buy from Morgan Stanley

- TipRanks. All rights reserved.

News

Stocktwits